Johnson & Johnson (JNJ)

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.

Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.

Things are going well for the pharmaceutical giant.

Johnson & Johnson expands its biotech pipeline with Firefly Bio acquisition and a strategic partnership with Sail Biomedicines.

But is that performance sustainable?

Johnson & Johnson's revenue has grown modestly while Eli Lilly's revenue has nearly doubled in two years, narrowing a once-wide gap.

Johnson & Johnson reached a $5.5 billion agreement to resolve remaining federal and state talc litigation over ovarian cancer claims.

U.S. stock futures were mixed on Tuesday, as the Dow Jones index gained but the S&P 500 and Nasdaq 100 indices declined.

This value ETF offers a great value for investors right now.

Both have very promising futures.

A name that's often ignored by investors due to its limited historic growth is evolving into a solid income-growth prospect.

There are plenty of reasons to love these companies.

FDA grants De Novo authorization for Johnson & Johnson's OTTAVA robotic surgical system for general surgery procedures.